Posted by Michael Wonder on 17 Dec 2018
PHARMAC funding decision gives Kiwis with hepatitis C access to a potential cure
17 December 2018 - Life changing treatment for New Zealanders living with hepatitis C will be available from 1 February 2019, after PHARMAC funds a new treatment.
The medicine known as Maviret (glecaprevir and pibrentasvir) can be prescribed to people with hepatitis C regardless of the type of hepatitis C virus they have.
Director of Operations, Lisa Williams, says that funding Maviret means that most people with hepatitis C will now have the opportunity to access a funded treatment that has the potential to cure hepatitis C.
